Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases

Annals of the New York Academy of Sciences

Volumn 1147, Issue , 2008, Pages 112-121

  Szeto, Hazel H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Antioxidants; Apoptosis; Mitochondrial permeability transition; MPTP; Parkinson's disease; Reactive oxygen species

Indexed keywords

2',6' DIMETHYLTYROSINE DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; ADENOSINE TRIPHOSPHATE; AROMATIC CARBOXYLIC ACID; DEXTRO ARGININE 2',6' DIMETHYLTYROSINE LYSYLPHENYLALANINAMIDE; PEPTIDE DERIVATIVE; PHENYLALANINE DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BLOOD BRAIN BARRIER; CELL DEATH; CELL PROTECTION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DELIVERY SYSTEM; HUMAN; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN TARGETING;

ANIMALIA;

EID: 57649187112     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1427.013     Document Type: Conference Paper

References (65)

1. Lin, M.T. & M.F. Beal. 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 : 787 795.
2. Trushina, E. & C.T. Mcmurray. 2007. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145 : 1233 1248.
3. Parihar, M.S. & G.J. Brewer. 2007. Mitoenergetic failure in Alzheimer disease. Am. J. Physiol. Cell Physiol. 292 : C8 C23.
4. Dodson, M.W. & M. Guo. 2007. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol. 17 : 331 337.
5. Lustbader, J.W., M. Cirilli, C. Lin, et al. 2004. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 : 448 452.
6. Crouch, P.J., R. Blake, J.A. Duce, et al. 2005. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 25 : 672 679.
7. Beckman, J.S., A.G. Estevez, J.P. Crow & L. Barbeito. 2001. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci. 24 : S15 S20.
8. Mattiazzi, M., M. D'aurelio, C.D. Gajewski, et al. 2002. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277 : 29626 29633.
9. Ferreirinha, F., A. Quattrini, M. Pirozzi, et al. 2004. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J. Clin. Invest. 113 : 231 242.
10. Beal, M.F. 2002. Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med. 32 : 797 803.
11. Sultana, R., M. Perluigi & D.A. Butterfield. 2006. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833 : 3 11.
12. Przedborski, S. & H. Ischiropoulos. 2005. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid. Redox. Signal. 7 : 685 693.
13. Andersen, J.K. 2004. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10 (Suppl S18 S25.
14. Choi, J., M.C. Sullards, J.A. Olzmann, et al. 2006. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281 : 10816 10824.
15. Przedborski, S., Q. Chen, M. Vila, et al. 2001. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76 : 637 640.
16. Abeliovich, A. & B.M. Flint. 2006. Parkinsonism genes: culprits and clues. J. Neurochem. 99 : 1062 1072.
17. Andres-Mateos, E., C. Perier, L. Zhang, et al. 2007. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. USA 104 : 14807 14812.
18. Rogers, J., D. Mastroeni, B. Leonard, et al. 2007. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int. Rev. Neurobiol. 82 : 235 246.
19. Whitton, P.S. 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 : 963 976.
20. Wu, D.C., P. Teismann, K. Tieu, et al. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100 : 6145 6150.
21. Zeevalk, G.D., L.P. Bernard, C. Song, et al. 2005. Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. Antioxid. Redox. Signal. 7 : 1117 1139.
22. Turrens, J.F. 2003. Mitochondrial formation of reactive oxygen species. J. Physiol. 552 : 335 344.
23. Andreyev, A.Y., Y.E. Kushnareva & A.A. Starkov. 2005. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc.). 70 : 200 214.
24. Liu, Y., G. Fiskum & D. Schubert. 2002. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80 : 780 787.
25. Adam-Vizi, V. & C. Chinopoulos. 2006. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 27 : 639 645.
26. Starkov, A.A., G. Fiskum, C. Chinopoulos, et al. 2004. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J. Neurosci. 24 : 7779 7788.
27. Tretter, L. & V. Dam-Vizi. 2004. Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J. Neurosci. 24 : 7771 7778.
28. Petrosillo, G., F.M. Ruggiero & G. Paradies. 2003. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J. 17 : 2202 2208.
29. Shidoji, Y., K. Hayashi, S. Komura, et al. 1999. Loss of molecular interaction between cytochrome c and cardiolipin due to lipid peroxidation. Biochem. Biophys. Res Commun. 264 : 343 347.
30. Chen, Q. & E.J. Lesnefsky. 2006. Depletion of cardiolipin and cytochrome c during ischemia increases hydrogen peroxide production from the electron transport chain. Free Radic. Biol. Med. 40 : 976 982.
31. Li, P., D. Nijhawan, I. Budihardjo, et al. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 : 479 489.
32. Green, D.R. & J.C. Reed. 1998. Mitochondria and apoptosis. Science 281 : 1309 1312.
33. Zou, H., Y. Li, X. Liu & X. Wang. 1999. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274 : 11549 11556.
34. Szeto, H.H. 2006. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS. J. 8 : E521 E531.
35. Beal, M.F. 2003. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53 (Suppl 3 S39 S47.
36. Murphy, M.P. & R.A. Smith. 2007. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47 : 629 656.
37. Fink, M.P., C.A. Macias, J. Xiao, et al. 2007. Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted anti-oxidants. Biochem. Pharmacol. 74 : 801 809.
38. Armstrong, J.S. 2007. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. 151 : 1154 1165.
39. Szeto, H.H. 2008. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid. Redox. Signal. 10 : 601 619.
40. Schiller, P.W., T.M. Nguyen, N.N. Chung & C. Lemieux. 1989. Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity. J. Med. Chem. 32 : 698 703.
41. Schiller, P.W., T.M. Nguyen, I. Berezowska, et al. 2000. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 35 : 895 901.
42. Szeto, H.H., J.L. Lovelace, G. Fridland, et al. 2001. In vivo pharmacokinetics of selective mu-opioid peptide agonists. J. Pharmacol. Exp. Ther. 298 : 57 61.
43. Zhao, K., G. Luo, G.M. Zhao, et al. 2003. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J. Pharmacol. Exp. Ther. 304 : 425 432.
44. Zhao, K., G. Luo, S. Giannelli & H.H. Szeto. 2005. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem. Pharmacol. 70 : 1796 1806.
45. Zhao, K., G.M. Zhao, D. Wu, et al. 2004. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 279 : 34682 34690.
46. Starkov, A.A. & G. Fiskum. 2003. Regulation of brain mitochondrial H2O2 production by membrane potential and NAD(P)H redox state. J. Neurochem. 86 : 1101 1107.
47. Petri, S., M. Kiaei, M. Damiano, et al. 2006. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 98 : 1141 1148.
48. Rosen, D.R., T. Siddique, D. Patterson, et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 : 59 62.
49. Gurney, M.E., H. Pu, A.Y. Chiu, et al. 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 : 1772 1775.
50. Ferrante, R.J., S.E. Browne, L.A. Shinobu, et al. 1997. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69 : 2064 2074.
51. Beal, M.F., R.J. Ferrante, S.E. Browne, et al. 1997. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42 : 644 654.
52. Vijayvergiya, C., M.F. Beal, J. Buck & G. Manfredi. 2005. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J. Neurosci. 25 : 2463 2470.
53. Pasinelli, P., M.E. Belford, N. Lennon, et al. 2004. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43 : 19 30.
54. Przedborski, S., K. Tieu, C. Perier & M. Vila. 2004. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 36 : 375 379.
55. Betarbet, R., T.B. Sherer, G. Mackenzie, et al. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 : 1301 1306.
56. Ramsay, R.R., J.I. Salach & T.P. Singer. 1986. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 134 : 743 748.
57. Cassarino, D.S., J.K. Parks, W.D. Parker, Jr. & J.P. Bennett, Jr. 1999. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta 1453 : 49 62.
58. Ramsay, R.R. & T.P. Singer. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261 : 7585 7587.
59. Szeto, H.H. 2007. Mitochondria-Targeted Cytoprotective Peptides for Ischemia-Reperfusion Injury. Antioxid. Redox. Signal. Epub doi :.
60. Lotharius, J. & K.L. O'Malley. 2000. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 : 38581 38588.
61. Chen, X.C., F. Fang, Y.G. Zhu, et al. 2003. Protective effect of ginsenoside Rg1 on MPP+-induced apoptosis in SHSY5Y cells. J. Neural Transm. 110 : 835 845.
62. Kalivendi, S.V., S. Kotamraju, S. Cunningham, et al. 2003. 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem. J. 371 : 151 164.
63. Storch, A., A.C. Ludolph & J. Schwarz. 1999. HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism. Neurochem. Int. 35 : 393 403.
64. Fonck, C. & M. Baudry. 2001. Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation. Brain Res. 905 : 199 206.
65. Lee, C.S., W.J. Park, H.H. Ko & E.S. Han. 2006. Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine. Mol. Cell Biochem. 289 : 193 200.